1. Home
  2. CBIO vs ASLE Comparison

CBIO vs ASLE Comparison

Compare CBIO & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$10.83

Market Cap

389.7M

Sector

N/A

ML Signal

HOLD

Logo AerSale Corporation

ASLE

AerSale Corporation

HOLD

Current Price

$7.39

Market Cap

356.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
ASLE
Founded
2003
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
389.7M
356.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CBIO
ASLE
Price
$10.83
$7.39
Analyst Decision
Strong Buy
Hold
Analyst Count
6
2
Target Price
$27.17
$7.00
AVG Volume (30 Days)
142.5K
256.0K
Earning Date
02-23-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.11
Revenue
N/A
$339,090,000.00
Revenue This Year
N/A
$1.35
Revenue Next Year
N/A
$19.09
P/E Ratio
N/A
$67.84
Revenue Growth
N/A
N/A
52 Week Low
$9.81
$5.56
52 Week High
$21.40
$9.12

Technical Indicators

Market Signals
Indicator
CBIO
ASLE
Relative Strength Index (RSI) 37.86 50.39
Support Level $10.56 $7.30
Resistance Level $14.71 $7.68
Average True Range (ATR) 1.01 0.24
MACD -0.07 -0.04
Stochastic Oscillator 6.14 15.97

Price Performance

Historical Comparison
CBIO
ASLE

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About ASLE AerSale Corporation

AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.

Share on Social Networks: